title: Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer: A Review.
abstract: Ever since the critical role of androgen deprivation therapy for the treatment of metastatic prostate cancer was established, several trials aimed to show an improved outcome with the early introduction of chemotherapy in metastatic disease. Until recently, all these trials-including the GETUG-AFU 15 trial-failed to confirm an improvement in survival. The recently published CHAARTED and STAMPEDE trials showed a striking benefit and changed the standard of care for patients with newly diagnosed metastatic prostate cancer. We summarize the evidence that emerged from these trials that support the use of combined chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
authors.affiliation: From the University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI.
authors.forename: Christos E
authors.initials: CE
authors.lastname: Kyriakopoulos
authors.forename: Glenn
authors.initials: G
authors.lastname: Liu
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic
chemical_list: D018931:Antineoplastic Agents, Hormonal